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a continuous improvement was noted in sustained virological
response, from 13% with IFN monotherapy to 31% with PEG-
IFN +RBV, while even a 48% sustained virological response
has been achieved in the prospective trial. The predictors
of outcome were the 4-week ‘rapid’ and 12-week ‘early’
virological responses, female gender, age, BMI and adher-
ence. The most frequent complications of the treatment
were cytopenia, haemolysis and depression, occurring in 9%
of patients.
Conclusion: Unlike in HBV infection, in HCV hepatitis the
efﬁcacy of antiviral treatment has gradually improved in our
everyday clinical practice. To manage the growing popula-
tions of hard-to-treat patients with chronic viral hepatitis,
there is a need for more effective treatment modalities,
including optimised, individualised dosing and novel antivi-
ral agents.
doi:10.1016/j.ijid.2008.05.1258
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Aims: Since in the outcome of chronic hepatitis C virus
(HCV) infection the progression of hepatic ﬁbrosis is essen-
tial, and interferon (IFN) treatment is supposed to inhibit
ﬁbrogenesis, we wanted to compare changes in three non-
invasive ﬁbrosis markers in chronic HCV hepatitis.
Methods: Plasma levels of TGF-beta1 and hyaluronic acid
(HA) were determined by ELISA, procollagen-III-peptide (P-
III-P) levels by RIA in 49 patients with chronic hepatitis C
before the antiviral treatment and 1, 3, 6 and 12 months
thereafter. Twenty two patients became responders (R), 27
patients were non-responders (NR). Thirty healthy controls
were also studied. Correlation between TGF-beta1, HA, P-
III-P levels and the histological activity and the ﬁbrosis score
in liver biopsy was evaluated.
Results: Pretreatment plasma TGF-beta1, HA and P-
III-P levels were signiﬁcantly (p < 0,01) increased in both
responder and non-responder patients compared to con-
trols. HA levels correlated with ﬁbrosis score, TGF-beta1
with histological activity index. PEG-IFN + ribavirin treat-
ment decreased both TGF-beta1 and HA levels, not only
in responders but also in non-responders. The reduction of
ﬁbrosis marker levels was more considerable after 6 months
of antiviral therapy, and remained sustained even 6 months
after the treatment. No correlation was found betwen ﬁbro-
sis markers and HCV RNA levels.
Conclusion: PEG-IFN plus Ribavirin treatment decreased
TGF-beta1 and hyaluronic acid levels independently of
virological response. These data suggest that antiviral
treatment may have antiﬁbrotic effect even in virological
non-responders.
doi:10.1016/j.ijid.2008.05.1259
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Infections with HBV and HCV are the most common cause
of chronic hepatitis and their consequence may be liver cir-
rhosis and/or hepatocellular carcinoma. Co-infection with
these viruses is relatively common and it remains serious
epidemiological and clinical problem.
Objective: Evaluation of impact of co-infection with HBV
and HCV on clinical picture of chronic hepatitis.
Material and Methods: retrospective analysis of 238
patients among 1330 patients hospitalized in years
2001—2005 in Department of Infectious Diseases in Wro-
claw due to diagnostics of chronic hepatitis C. Patients
were divided into groups according to their serological sta-
tus: group A - anti-HCV positive, anti-HBc negative patients
(n = 123), group B - anti-HCV positive, anti-HBc positive,
HBsAg negative patients (n = 115). Groups A and B were
randomly selected according to age, sex, duration of HCV
infection. Some biochemical features, histological pattern
(modiﬁed HAI scale) and virological status were evaluated.
Dates were statistical analyzed by chi-square Wald test.
Results: Median value of viral load in group A was
1,4× 106 and in group B was 1,0× 106 (p > 0,05). There were
no statistical correlation of GOT, GPT, GGTP and PLT values
in these two groups. Grading in group A was 1,64 and in
group B was 1,62 (p > 0,5). Relevant differences in ﬁbrosis
stage was observed between the groups - staging in group A
was 1,87 and in group B 1,37 (p < 0,05)).
Conclusions: Past HBV infection and possible minireplica-
tion has no impact on HCV viremia. Fibrosis of the liver was
surprisingly higher in HCV monoinfection patients. Further
investigation in large and homogenous groups of patients are
needed.
doi:10.1016/j.ijid.2008.05.1247
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Background: Current therapy for HCV consists of a com-
bination of synthetically-modiﬁed interferon, pegylated
interferon, and ribavirin, to which nearly 50% of patients
do not respond. Clinical trials have demonstrated that this
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clinical response rate is genotype speciﬁc in chronic infec-
tions, even after accounting for host factors such as sex,
age, degree of ﬁbrosis and ethnicity. The difference in clin-
ical response rates among HCV genotypes has yet to be
explained. Because HCV genotypes likely diverged hundreds
of years ago, viral elements that confer clinical resistance
would be relatively ancient and subsequently conserved by
natural selection.
Methods: We used the full-length genome sequences of
all 346 full-length HCV genomic sequences to perform a com-
prehensive, rigorous phylogenetic analysis using distance,
maximum likelihood and parsimony-based optimality crite-
ria. We then used the robust phylogeny as a template for
mapping clinical resistance data and inferring an evolution-
ary pattern of genotype speciﬁc change. In addition, we used
character reconstruction methods to infer sequence changes
that correlate with changing resistance. We also applied
population genetic methods to infer the relative ages of HCV
genotypes for comparison with our phylogenetic methods.
Results: The phylogeny that resulted from our analyses,
depicting the evolutionary history of HCV and the relative
branching order of each of the major genotypes, shows a
trend toward increasing interferon resistance as each new
genotype diverged from a common ancestral lineage. We
identiﬁed several key amino acid residues that may be
responsible for increasing interferon therapy resistance.
Conclusion: Our results suggest that the branching age of
each genotype is predictive of the relative rates of response
to therapy. The apparent paradox of how the modern ther-
apy of interferon injections could select for an ancient,
adaptive trait, may be explained by ancient selective pres-
sure from natural innate immune systems.
doi:10.1016/j.ijid.2008.05.1248
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Background: The role of Hepatitis G Virus (HGV) in the
pathogenesis of chronic liver disease has long been debated.
HGV positivity has been reported at varying rates from
around the world; however, there is insufﬁcient data regard-
ing co-infection status and prevalence in our part of the
world. Hence, the primary objective of this study was to
determine the prevalence of HGV among chronic liver dis-
ease (CLD) patients and apparently healthy voluntary blood
donors in Kerala. The secondary objective was to evaluate
the co-infection status of HGV along with HBV and/or HCV.
Methods: The study group consisted of 60 serum samples
of which 26 were from patients with chronic liver disease and
34 from healthy voluntary blood donors. Viral RNA isolated
from the serum samples was ampliﬁed and tested for HGV
by nested RT-PCR using primers. The positive samples were
subjected to RFLP analysis and sequencing of amplicons to
conﬁrm the presence of HGV RNA. The HBV/HCV positivity
of all samples were collected and compared with HGV RNA
positivity to establish co-infection status
Results: Out of 60 samples studied, 28 (46.7%) were pos-
itive for HGV RNA. Between the study groups, CLD patients
exhibited higher prevalence (50%) compared to the volun-
tary blood donors (44%). Co-infection of HGV with HBV/HCV
was more among the CLD patients (61.5%) as compared to
voluntary blood donors (36.3%) whereas isolated HGV infec-
tion was more common in the voluntary blood donor group
(58.3%) as compared to CLD patients (38.4%). Among the
CLD patients, HGV positivity was observed in 71.4% of the
HCV positive samples compared to 50% of the HBV positive
samples.
Conclusion: Our study reports a higher incidence of HGV
RNA positivity among both CLD patients and voluntary blood
donors in Kerala as compared to reports from other parts
of India. The study also reﬂects a higher incidence of HGV
co-infection with HCV/HBV among the CLD patients as com-
pared to a higher rate of isolated HGV infection among
apparently healthy voluntary blood donors. These observa-
tions probably point to a role for HGV in increasing the risk
for chronic liver disease as a co-infection though it may not
be a causative agent on its own.
doi:10.1016/j.ijid.2008.05.1249
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Background and aim: Chronic infection of hepatitis C
virus (HCV) may lead to hepatic ﬁbrosis and the precise
mechanisms remain unclear.
Methods: In this study, hepatic stellate cells (HSC) were
transiently transfected with a HCV E2-expression vector and
subjected to semi-quantitative RT-PCR and western blotting
to see the impact of E2 protein on the expression levels of
certain molecules involved in ﬁbrogenesis
Results: The expression of E2 protein may promote
the expression of alpha-smooth muscle actin, and colla-
gen alpha(I) in a time-dependent fashion. Furthermore,
mRNA levels of several pro-ﬁbrosis or pro-inﬂammatory
cytokines, including TGF-1, connective tissue growth fac-
tor (CTGF), IL-6 and IL-1, were signiﬁcantly increased in
E2 transfected-HSC cell lines, while the protein level and
activity of MMP-s are also considerably increased.
Conclusion: Taken together, E2 protein may involve in the
hepatic ﬁbrogenesis via an up-regulation of ﬁbrosis-related
proteins.
doi:10.1016/j.ijid.2008.05.1250
